226. Interstitial cystitis with Hunners ulcer Clinical trials / Disease details
Clinical trials : 143 / Drugs : 171 - (DrugBank : 56) / Drug target genes : 64 - Drug target pathways : 145
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01060254 (ClinicalTrials.gov) | April 6, 2010 | 29/1/2010 | A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain | A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome | Cystitis, Interstitial;Urologic Diseases;Urinary Bladder Diseases;Cystitis | Drug: Placebo;Drug: JNJ-42160443 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | NULL | Terminated | 18 Years | 80 Years | All | 31 | Phase 2 | United States;Canada |